Search

Your search keyword '"Sattui, Sebastian"' showing total 264 results
Start Over Author "Sattui, Sebastian"
264 results on '"Sattui, Sebastian"'

3. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.

Author

Dejaco, Christian, Kerschbaumer, Andreas, Aletaha, Daniel, Bond, Milena, Hysa, Elvis, Camellino, Dario, Ehlers, Lisa, Abril, Andy, Appenzeller, Simone, Cid, Maria, Dasgupta, Bhaskar, Duftner, Christina, Grayson, Peter, Hellmich, Bernhard, Hočevar, Alojzija, Kermani, Tanaz, Matteson, Eric, Mollan, Susan, Neill, Lorna, Ponte, Cristina, Salvarani, Carlo, Sattui, Sebastian, Schmidt, Wolfgang, Seo, Philip, Smolen, Josef, Thiel, Jens, Toro-Gutiérrez, Carlos, Whitlock, Madeline, and Buttgereit, Frank

Subjects
Biological Therapy, Giant Cell Arteritis, Outcome and Process Assessment, Health Care, Polymyalgia Rheumatica, Humans, Giant Cell Arteritis, Polymyalgia Rheumatica, Quality of Life, Comorbidity
Abstract

OBJECTIVES: To develop treat-to-target (T2T) recommendations in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). METHODS: A systematic literature review was conducted to retrieve data on treatment targets and outcomes in GCA/PMR as well as to identify the evidence for the effectiveness of a T2T-based management approach in these diseases. Based on evidence and expert opinion, the task force (29 participants from 10 countries consisting of physicians, a healthcare professional and a patient) developed recommendations, with consensus obtained through voting. The final level of agreement was provided anonymously. RESULTS: Five overarching principles and six-specific recommendations were formulated. Management of GCA and PMR should be based on shared decisions between patient and physician recognising the need for urgent treatment of GCA to avoid ischaemic complications, and it should aim at maximising health-related quality of life in both diseases. The treatment targets are achievement and maintenance of remission, as well as prevention of tissue ischaemia and vascular damage. Comorbidities need to be considered when assessing disease activity and selecting treatment. CONCLUSION: These are the first T2T recommendations for GCA and PMR. Treatment targets, as well as strategies to assess, achieve and maintain these targets have been defined. The research agenda highlights the gaps in evidence and the need for future research.

Published
2024

4. Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status.

Author

Maguire, Sinead, Al-Emadi, Samar, Alba, Paula, Aguiar, Mathia, Al Lawati, Talal, Alle, Gelsomina, Bermas, Bonnie, Bhana, Suleman, Branimir, Anic, Bulina, Inita, Clowse, Megan, Cogo, Karina, Colunga, Iris, Cook, Claire, Cortez, Karen, Dao, Kathryn, Gianfrancesco, Milena, Gore-Massey, Monique, Gossec, Laure, Grainger, Rebecca, Hausman, Jonathon, Hsu, Tiffany, Hyrich, Kimme, Isnardi, Carolina, Kawano, Yumeko, Kilding, Rachael, Kusevich, Daria, Lawson-Tovey, Saskia, Liew, Jean, McCarthy, Eoghan, Montgumery, Anna, Moyano, Sebastian, Nasir, Noreen, Padjen, Ivan, Papagoras, Charalampos, Patel, Naomi, Pera, Mariana, Pisoni, Cecilia, Pons-Estel, Guillermo, Quiambao, Antonio, Quintana, Rosana, Ruderman, Eric, Sattui, Sebastian, Savio, Veronica, Sciascia, Savino, Sencarova, Marieta, Morales, Rosa, Siddique, Faizah, Sirotich, Emily, Sparks, Jeffrey, Strangfeld, Anja, Sufka, Paul, Tanner, Helen, Tissera, Yohana, Wallace, Zachary, Werner, Marina, Wise, Leanna, Worthing, Angus, Zell, JoAnn, Zepa, Julija, Machado, Pedro, Yazdany, Jinoos, Robinson, Philip, and Conway, Richard

Subjects
COVID-19, patient outcomes, pregnancy, rheumatic disease, vaccination, women’s health, Pregnancy, Infant, Newborn, Female, Humans, COVID-19 Vaccines, COVID-19, COVID-19 Testing, Rheumatic Diseases, Premature Birth, Vaccination
Abstract

OBJECTIVE: To describe obstetric outcomes based on COVID-19 vaccination status, in women with rheumatic and musculoskeletal diseases (RMDs) who developed COVID-19 during pregnancy. METHODS: Data regarding pregnant women entered into the COVID-19 Global Rheumatology Alliance registry from 24 March 2020-25 February 2022 were analysed. Obstetric outcomes were stratified by number of COVID-19 vaccine doses received prior to COVID-19 infection in pregnancy. Descriptive differences between groups were tested using the chi-squared or Fishers exact test. RESULTS: There were 73 pregnancies in 73 women with RMD and COVID-19. Overall, 24.7% (18) of pregnancies were ongoing, while of the 55 completed pregnancies, 90.9% (50) of pregnancies resulted in livebirths. At the time of COVID-19 diagnosis, 60.3% (n = 44) of women were unvaccinated, 4.1% (n = 3) had received one vaccine dose while 35.6% (n = 26) had two or more doses. Although 83.6% (n = 61) of women required no treatment for COVID-19, 20.5% (n = 15) required hospital admission. COVID-19 resulted in delivery in 6.8% (n = 3) of unvaccinated women and 3.8% (n = 1) of fully vaccinated women. There was a greater number of preterm births (PTB) in unvaccinated women compared with fully vaccinated 29.5% (n = 13) vs 18.2% (n = 2). CONCLUSIONS: In this descriptive study, unvaccinated pregnant women with RMD and COVID-19 had a greater number of PTB compared with those fully vaccinated against COVID-19. Additionally, the need for COVID-19 pharmacological treatment was uncommon in pregnant women with RMD regardless of vaccination status. These results support active promotion of COVID-19 vaccination in women with RMD who are pregnant or planning a pregnancy.

Published
2023

5. Rapid Adoption of Telemedicine in Rheumatology Care During the COVID‐19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees

Author

Yeoh, Su‐Ann, Young, Kristen, Putman, Michael, Sattui, Sebastian, Conway, Richard, Graef, Elizabeth, Kilian, Adam, Konig, Maximilian, Sparks, Jeffrey, Ugarte‐Gil, Manuel, Upton, Laura, Berenbaum, Francis, Bhana, Suleman, Costello, Wendy, Hausmann, Jonathan, Machado, Pedro, Robinson, Philip, Sirotich, Emily, Sufka, Paul, Yazdany, Jinoos, Liew, Jean, Grainger, Rebecca, Wallace, Zachary, Jayatilleke, Arundathi, and Alliance, The Global Rheumatology

Subjects
Health Services, Clinical Research, Networking and Information Technology R&D (NITRD), Good Health and Well Being, Global Rheumatology Alliance
Abstract

ObjectiveTo evaluate the impact of telemedicine use during the coronavirus disease 2019 (COVID-19) pandemic on rheumatology trainees.MethodsA voluntary, anonymous, web-based survey was administered in English, Spanish, or French from August 19 to October 5, 2020. Adult and pediatric rheumatology trainees were invited to participate via social media and email. Using multiple-choice questions and Likert scales, the survey assessed prior and current telemedicine use, impact on training, and supervision after COVID-19 prompted rapid telemedicine implementation.ResultsSurveys were received from 302 trainees from 33 countries, with 83% in adult rheumatology training programs. Reported telemedicine use increased from 13% before the pandemic to 82% during the pandemic. United States trainees predominantly used video visits, whereas outside the United States telemedicine was predominantly audio only. Most (65%) evaluated new patients using telemedicine. More respondents were comfortable using telemedicine for follow-up patients (69%) than for new patients (25%). Only 39% of respondents reported receiving telemedicine-focused training, including instruction on software, clinical skills, and billing, whereas more than half of United States trainees (59%) had training. Postconsultation verbal discussion was the most frequent form of supervision; 24% reported no supervision. Trainees found that telemedicine negatively impacted supervision (50%) and the quality of clinical teaching received (70%), with only 9% reporting a positive impact.ConclusionsDespite widespread uptake of telemedicine, a low proportion of trainees received telemedicine training, and many lacked comfort in evaluating patients, particularly new patients. Inadequate supervision and clinical teaching were areas of concern. If telemedicine remains in widespread use, ensuring appropriate trainee supervision and teaching should be prioritized.

Published
2022

6. The impact of COVID-19 on rheumatology training—results from the COVID-19 Global Rheumatology Alliance trainee survey

Author

Young, Kristen, Yeoh, Su-Ann, Putman, Michael, Sattui, Sebastian, Conway, Richard, Graef, Elizabeth, Kilian, Adam, Konig, Maximilian, Sparks, Jeffrey, Ugarte-Gil, Manuel, Upton, Laura, Berenbaum, Francis, Bhana, Suleman, Costello, Wendy, Hausmann, Jonathan, Machado, Pedro, Robinson, Philip, Sirotich, Emily, Sufka, Paul, Yazdany, Jinoos, Liew, Jean, Grainger, Rebecca, Wallace, Zachary, and Jayatilleke, Arundathi

Subjects
Good Health and Well Being, Medical Education, COVID-19, Rheumatology Fellowship
Published
2022

7. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

Author

Sattui, Sebastian E, Conway, Richard, Putman, Michael S, Seet, Andrea M, Gianfrancesco, Milena A, Beins, Kaley, Hill, Catherine, Liew, David, Mackie, Sarah L, Mehta, Puja, Neill, Lorna, Gomez, Gimena, Salinas, Maria Isabel Haye, Maldonado, Federico Nicolas, Mariz, Henrique Ataide, de Sousa Studart, Samia Araujo, Araujo, Nafice Costa, Knight, Ann, Rozza, Davide, Quartuccio, Luca, Samson, Maxime, Bally, Stéphane, Maria, Alexandre TJ, Chazerain, Pascal, Hasseli, Rebecca, Müller-Ladner, Ulf, Hoyer, Bimba F, Voll, Reinhard, Torres, Rita Pinheiro, Luis, Mariana, Ribeirio, Sandra Lucia Euzebio, Al-Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y-T, D’Silva, Kristin M, Patel, Naomi J, Wise, Leanna, Gilbert, Emily, Almada, Maria Valenzuela, Duarte-García, Alí, Ugarte-Gil, Manuel, Jacobsohn, Lindsay, Izadi, Zara, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Sirotich, Emily, Hausmann, Jonathan S, Sufka, Paul, Bhana, Suleman, Liew, Jean W, Grainger, Rebecca, Machado, Pedro M, Wallace, Zachary S, Yazdany, Jinoos, Robinson, Philip C, Alliance, Global Rheumatology, Dahou, Brahim, Rath, Eva, Piette, Yves, Devinck, Mieke, Maeyaert, Bea, Ribeiro, Francinne Machado, Ribeiro, Sandra Lucia Euzebio, Pinheiro, Marcelo, Quintana, Rosana, Gómez, Gimena, Roberts, Karen, Baez, Roberto Miguel, Coello, Vanessa Castro, Salinas, María J Haye, Torres, Alvaro Andres Reyes, Alle, Gelsomina, Tanten, Romina, Ficco, Hernán Maldonado, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan Alejandro, Schmid, Maria Marcela, Cosatti, Micaela, Gamba, Maria Julieta, Leandro, Carlevaris, Cusa, María Alejandra, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Elkin, Maria Soledad Gálvez, Medina, María Alejandra, and Savio, Veronica

Subjects
Aging, Arthritis, Autoimmune Disease, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Inflammatory and immune system, Global Rheumatology Alliance
Abstract

BackgroundPatients with primary systemic vasculitis or polymyalgia rheumatica might be at a high risk for poor COVID-19 outcomes due to the treatments used, the potential organ damage cause by primary systemic vasculitis, and the demographic factors associated with these conditions. We therefore aimed to investigate factors associated with COVID-19 outcomes in patients with primary systemic vasculitis or polymyalgia rheumatica.MethodsIn this retrospective cohort study, adult patients (aged ≥18 years) diagnosed with COVID-19 between March 12, 2020, and April 12, 2021, who had a history of primary systemic vasculitis (antineutrophil cytoplasmic antibody [ANCA]-associated vasculitis, giant cell arteritis, Behçet's syndrome, or other vasculitis) or polymyalgia rheumatica, and were reported to the COVID-19 Global Rheumatology Alliance registry were included. To assess COVID-19 outcomes in patients, we used an ordinal COVID-19 severity scale, defined as: (1) no hospitalisation; (2) hospitalisation without supplemental oxygen; (3) hospitalisation with any supplemental oxygen or ventilation; or (4) death. Multivariable ordinal logistic regression analyses were used to estimate odds ratios (ORs), adjusting for age, sex, time period, number of comorbidities, smoking status, obesity, glucocorticoid use, disease activity, region, and medication category. Analyses were also stratified by type of rheumatic disease.FindingsOf 1202 eligible patients identified in the registry, 733 (61·0%) were women and 469 (39·0%) were men, and their mean age was 63·8 years (SD 17·1). A total of 374 (31·1%) patients had polymyalgia rheumatica, 353 (29·4%) had ANCA-associated vasculitis, 183 (15·2%) had giant cell arteritis, 112 (9·3%) had Behçet's syndrome, and 180 (15·0%) had other vasculitis. Of 1020 (84·9%) patients with outcome data, 512 (50·2%) were not hospitalised, 114 (11·2%) were hospitalised and did not receive supplemental oxygen, 239 (23·4%) were hospitalised and received ventilation or supplemental oxygen, and 155 (15·2%) died. A higher odds of poor COVID-19 outcomes were observed in patients who were older (per each additional decade of life OR 1·44 [95% CI 1·31-1·57]), were male compared with female (1·38 [1·05-1·80]), had more comorbidities (per each additional comorbidity 1·39 [1·23-1·58]), were taking 10 mg/day or more of prednisolone compared with none (2·14 [1·50-3·04]), or had moderate, or high or severe disease activity compared with those who had disease remission or low disease activity (2·12 [1·49-3·02]). Risk factors varied among different disease subtypes.InterpretationAmong patients with primary systemic vasculitis and polymyalgia rheumatica, severe COVID-19 outcomes were associated with variable and largely unmodifiable risk factors, such as age, sex, and number of comorbidities, as well as treatments, including high-dose glucocorticoids. Our results could be used to inform mitigation strategies for patients with these diseases.FundingAmerican College of Rheumatology and the European Alliance of Associations for Rheumatology.

Published
2021

10. Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases

Author

Hausmann, Jonathan S, Kennedy, Kevin, Simard, Julia F, Liew, Jean W, Sparks, Jeffrey A, Moni, Tarin T, Harrison, Carly, Larché, Maggie J, Levine, Mitchell, Sattui, Sebastian E, Semalulu, Teresa, Foster, Gary, Surangiwala, Salman, Thabane, Lehana, Beesley, Richard P, Durrant, Karen L, Mateus, Elsa F, Mingolla, Serena, Nudel, Michal, Palmerlee, Candace A, Richards, Dawn P, Liew, David FL, Hill, Catherine L, Bhana, Suleman, Costello, Wendy, Grainger, Rebecca, Machado, Pedro M, Robinson, Philip C, Sufka, Paul, Wallace, Zachary S, Yazdany, Jinoos, Sirotich, Emily, Alliance, COVID-19 Global Rheumatology, Sufka, Paul H, Singh, Namrata, Howard, Richard A, Kim, Alfred HJ, Westrich-Robertson, Tiffany, Tsui, Edmund, Duarte-Garcia, Ali, Tam, Herman, Jayatilleke, Arundathi, Konig, Maximilian F, Graef, Elizabeth R, Putman, Michael S, Syed, Reema H, Korsten, Peter, Mateus, Elsa, Laura, Upton A, Adam, Kilian, Chock, Yu Pei Eugenia, White, Douglas W, Zamora, Geraldine T, Traboco, Lisa S, Patel, Aarat M, Ugarte-Gil, Manuel F, Gianfrancesco, Milena A, Amigues, Isabelle, Sanchez-Alvarez, Catalina, Trupin, Laura, Jacobsohn, Lindsay R, Hoyer, Bimba F, Makan, Kavita, Gossec, Laure, Priyank, Chaudhary, Leipe, Jan, Wallace, Beth, Angeles-Han, Sheila T, Almaghlouth, Ibrahim A, Katherine, Wysham D, Padula, Anthony S, Berenbaum, Francis, Treemarcki, Erin M, Sinha, Rashmi, Lewandowski, Laura B, Webb, Kate, Young, Kristen J, Bulina, Inita, Uribe, Sebastian Herrera, Rubinstein, Tamar B, Nolan, Marc W, Ang, Elizabeth Y, Venuturupalli, Swamy R, Dubreuil, Maureen, Pisoni, Cecilia N, Cosatti, Micaela A, Campos, Jose, and Conway, Richard

Subjects
Arthritis, Aging, Autoimmune Disease, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Inflammatory and immune system, Good Health and Well Being, COVID-19 Global Rheumatology Alliance
Abstract

BackgroundThe impact and consequences of the COVID-19 pandemic on people with rheumatic disease are unclear. We developed the COVID-19 Global Rheumatology Alliance Patient Experience Survey to assess the effects of the COVID-19 pandemic on people with rheumatic disease worldwide.MethodsSurvey questions were developed by key stakeholder groups and disseminated worldwide through social media, websites, and patient support organisations. Questions included demographics, rheumatic disease diagnosis, COVID-19 diagnosis, adoption of protective behaviours to mitigate COVID-19 exposure, medication access and changes, health-care access and communication with rheumatologists, and changes in employment or schooling. Adults age 18 years and older with inflammatory or autoimmune rheumatic diseases were eligible for inclusion. We included participants with and without a COVID-19 diagnosis. We excluded participants reporting only non-inflammatory rheumatic diseases such as fibromyalgia or osteoarthritis.Findings12 117 responses to the survey were received between April 3 and May 8, 2020, and of these, 10 407 respondents had included appropriate age data. We included complete responses from 9300 adults with rheumatic disease (mean age 46·1 years; 8375 [90·1%] women, 893 [9·6%] men, and 32 [0·3%] participants who identified as non-binary). 6273 (67·5%) of respondents identified as White, 1565 (16·8%) as Latin American, 198 (2·1%) as Black, 190 (2·0%) as Asian, and 42 (0·5%) as Native American or Aboriginal or First Nation. The most common rheumatic disease diagnoses included rheumatoid arthritis (3636 [39·1%] of 9300), systemic lupus erythematosus (2882 [31·0%]), and Sjögren's syndrome (1290 [13·9%]). Most respondents (6921 [82·0%] of 8441) continued their antirheumatic medications as prescribed. Almost all (9266 [99·7%] of 9297) respondents adopted protective behaviours to limit SARS-CoV-2 exposure. A change in employment status occurred in 2524 (27·1%) of 9300) of respondents, with a 13·6% decrease in the number in full-time employment (from 4066 to 3514).InterpretationPeople with rheumatic disease maintained therapy and followed public health advice to mitigate the risks of COVID-19. Substantial employment status changes occurred, with potential implications for health-care access, medication affordability, mental health, and rheumatic disease activity.FundingAmerican College of Rheumatology.

Published
2021

11. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

Author

Sattui, Sebastian Eduardo, Liew, Jean W, Kennedy, Kevin, Sirotich, Emily, Putman, Michael, Moni, Tarin T, Akpabio, Akpabio, Alpízar-Rodríguez, Deshiré, Berenbaum, Francis, Bulina, Inita, Conway, Richard, Singh, Aman Dev, Duff, Eimear, Durrant, Karen L, Gheita, Tamer A, Hill, Catherine L, Howard, Richard A, Hoyer, Bimba F, Hsieh, Evelyn, Kibbi, Lina El, Kilian, Adam, Kim, Alfred Hyoungju, Liew, David FL, Lo, Chieh, Miller, Bruce, Mingolla, Serena, Nudel, Michal, Palmerlee, Candace A, Singh, Jasvinder A, Singh, Namrata, Ugarte-Gil, Manuel Francisco, Wallace, John, Young, Kristen J, Bhana, Suleman, Costello, Wendy, Grainger, Rebecca, Machado, Pedro M, Robinson, Philip C, Sufka, Paul, Wallace, Zachary S, Yazdany, Jinoos, Harrison, Carly, Larché, Maggie, Levine, Mitchell, Foster, Gary, Thabane, Lehana, Rider, Lisa G, Hausmann, Jonathan S, Simard, Julia F, and Sparks, Jeffrey A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Aging, Immunization, Prevention, Autoimmune Disease, Arthritis, Vaccine Related, 6.1 Pharmaceuticals, Prevention of disease and conditions, and promotion of well-being, Evaluation of treatments and therapeutic interventions, 3.4 Vaccines, Inflammatory and immune system, Good Health and Well Being, Adult, COVID-19, COVID-19 Vaccines, Female, Humans, Male, Middle Aged, Rheumatic Diseases, Rheumatology, SARS-CoV-2, Surveys and Questionnaires, Vaccination, vaccination, autoimmune diseases, Clinical sciences
Abstract

BackgroundWe describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine.MethodsFrom 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination.ResultsWe analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%.ConclusionAmong adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.

Published
2021

13. Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases

Author

Robinson, Philip C., Bhana, Suleman, Liew, Jean W., Sufka, Paul H., Singh, Namrata, Howard, Richard A., Kim, Alfred H.J., Westrich-Robertson, Tiffany, Sirotich, Emily, Tsui, Edmund, Duarte-Garcia, Ali, Sparks, Jeffrey A., Tam, Herman, Jayatilleke, Arundathi, Konig, Maximilian F., Graef, Elizabeth R., Putman, Michael S., Syed, Reema H., Korsten, Peter, Mateus, Elsa, Sattui, Sebastian E., Wallace, Zachary S., Laura, Upton A., Adam, Kilian, Chock, Yu Pei Eugenia, White, Douglas W., Zamora, Geraldine T., Traboco, Lisa S., Patel, Aarat M., Grainger, Rebecca, Ugarte-Gil, Manuel F., Gianfrancesco, Milena A., Amigues, Isabelle, Sanchez-Alvarez, Catalina, Trupin, Laura, Jacobsohn, Lindsay R., Beesley, Richard P., Hoyer, Bimba F., Machado, Pedro M., Makan, Kavita, Gossec, Laure, Priyank, Chaudhary, Leipe, Jan, Wallace, Beth, Angeles-Han, Sheila T., Almaghlouth, Ibrahim A., Katherine, Wysham D., Padula, Anthony S., Berenbaum, Francis, Treemarcki, Erin M., Sinha, Rashmi, Lewandowski, Laura B., Webb, Kate, Young, Kristen J., Bulina, Inita, Herrera Uribe, Sebastian, Rubinstein, Tamar B., Nolan, Marc W., Ang, Elizabeth Y., Venuturupalli, Swamy R., Hausmann, Jonathan S., Dubreuil, Maureen, Pisoni, Cecilia N., Cosatti, Micaela A., Campos, Jose, Simard, Julia F., Conway, Richard, Peterson, Tiffany M., Harrison, Carly O., Felix, Christele, Richards, Dawn P., Proulx, Laurie, Akpabio, Akpabio A., Worthing, Angus B., Laidlaw, Lynn R., Reid, Pankti, Palmerlee, Candace A., Danila, Maria I., Sahar, Lotfi-Emran, Linh, Ngo Q., Agarwal, Arnav, Studenic, Paul, Liew, David F.L., Larche, Maggie J., Mingolla, Serena A.M., Zamora, Erick A., Angevare, Saskya S., Sinha, Rashmi R., Durrant, Karen L.W., Peirce, Andrea, Somers, Emily C., Cappelli, Laura C., Frankel, Brittany A., Kumar, Bharat, Silinsky Krupnikova, Sonia D., Rosario Vega, Jorge A., Frankovich, Jourdan, Fernandez-Ruiz, Ruth, Posada Velásquez, Marcela, Yeoh, Su-Ann, Marino, Maria, Nudel, Michal, Scott, Chrisiaan, Rodríguez, Cecilia, Martín Mancheño, Ana I., Seo, Philip, Gamboa-Cárdenas, Rocío V., Pimentel-Quiroz, Victor R., Reátegui-Sokolova, Cristina, Kihara, Mari, Lin, Chung M.A., Kattula, Dheera, Laila, Girgis, Carmona, Loreto, Wallace, John, Yazdany, Jinoos, Costello, Wendy, Gore-massy, Monique C., Tomasella, Laura-Ann, Kodek, Moré A., Hausmann, Jonathan S, Kennedy, Kevin, Simard, Julia F, Liew, Jean W, Sparks, Jeffrey A, Moni, Tarin T, Harrison, Carly, Larché, Maggie J, Levine, Mitchell, Sattui, Sebastian E, Semalulu, Teresa, Foster, Gary, Surangiwala, Salman, Thabane, Lehana, Beesley, Richard P, Durrant, Karen L, Mateus, Elsa F, Mingolla, Serena, Palmerlee, Candace A, Richards, Dawn P, Liew, David F L, Hill, Catherine L, Machado, Pedro M, Robinson, Philip C, Sufka, Paul, and Wallace, Zachary S

Published
2021
Full Text
View/download PDF

16. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

Author

Dahou, Brahim, Rath, Eva, Piette, Yves, Devinck, Mieke, Maeyaert, Bea, Machado Ribeiro, Francinne, Euzebio Ribeiro, Sandra Lucia, Pinheiro, Marcelo, Quintana, Rosana, Gómez, Gimena, Roberts, Karen, Baez, Roberto Miguel, Castro Coello, Vanessa, Haye Salinas, María J., Maldonado, Federico Nicolas, Reyes Torres, Alvaro Andres, Alle, Gelsomina, Tanten, Romina, Maldonado Ficco, Hernán, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan Alejandro, Schmid, Maria Marcela, Cosatti, Micaela, Gamba, Maria Julieta, Leandro, Carlevaris, Cusa, María Alejandra, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Gálvez Elkin, Maria Soledad, Medina, María Alejandra, Savio, Veronica, Rojas Tessel, Ivana Romina, Perez Alamino, Rodolfo, Werner, Marina Laura, Ornella, Sofía, Casalla, Luciana, de la Vega, Maria, Severina, María, García, Mercedes, Gonzalez Lucero, Luciana, Romeo, Cecilia, Moyano, Sebastián, Barbich, Tatiana, Bertoli, Ana, Baños, Andrea, Petruzzelli, Sandra, Matellan, Carla, Conti, Silvana, Lazaro, Ma. Alicia, Rodriguez Gil, Gustavo Fabián, Risueño, Fabian, Quaglia, Maria Isabel, Scafati, Julia, Cuchiaro, Natalia Lili, Rebak, Jonathan Eliseo, Pineda, Susana Isabel, Calvo, María Elena, Picco, Eugenia, Gallino Yanzi, Josefina, Maid, Pablo, Guaglianone, Debora, Morbiducci, Julieta Silvana, Porta, Sabrina, Herscovich, Natalia, Velasco Zamora, José Luis, Kisluk, Boris, Castaños Menescardi, Maria Sol, Gallo, Rosana, Martire, María Victoria, Maldini, Carla, Goizueta, Cecilia, de la Vega Fernandez, Sabrina Solange, Aeschlimann, Carolina, Subils, Gisela, Ibáñez, Sebastián, Chassin-Trubert, Anne-Marie, Dong, Lingli, Cajas, Lui, Barešic, Marko, Anic, Branimir, Culo, Melanie-Ivana, Pavelic, Tea Ahel, Kovacevic Stranski, Kristina, Karanovic, Boris, Vencovsky, Jiri, Píchová, Marta, Filkova, Maria, Hamoud, Hesham, Vassilopoulos, Dimitrios, Guzman Melgar, Gabriela Maria, So, Ho, Király, Márta, Vojdanian, Mahdi, Balbir-Gurman, Alexandra, Abutiban, Fatemah, Zepa, Julija, Bulina, Inita, Bukauskiene, Loreta, Zaueta, Beatriz, Castillo Ortiz, Angel Alejandro, Zamora Tehozol, Erick, Vega, David, Cervántes Rosete, Diana, Martín Nares, Eduardo, Rodriguez-Reyna, Tatiana Sofia, Rull Gabayet, Marina, Alpízar-Rodríguez, Deshiré, Irazoque, Fedra, Jimenez, Xochitl, Geurts-van Bon, Lenny, Zijlstra, Theo, Hoekstra, Monique, Al-Adhoubi, Nasra, Salim, Babur, Giraldo, Enrique, Salinas, Ariel, Ugarte-Gil, Manuel, Nowakowski, Jaroslaw, Al-Emadi, Samar, Conway, Richard, Flood, Rachael, McCarthy, Geraldine, Felea, Ioana, Filipescu, Ileana, Rednic, Simona, Groseanu, Laura, Tamas, Maria Magdelena, Mlynarikova, Vanda, Skamlova, Martina, Zlnay, Martin, Miceková, Dagmar, Capova, Lubica, Macejova, Zelmira, Štenová, Emoke, Raffayova, Helena, Belakova, Gabriela, Strakova, Eva, Sencarová, Marieta, Žlnayová, Sona, Anna Sabová, Anna, Spisakova, Daniela, Oetterová, Mária, Lukacova, Olga, Bakosova, Martina, Hocevar, Alojzija, de la Torre-Rubio, Natalia, Alegre Sancho, Juan José, Corteguera Coro, Montserrat, Cobeta Garcia, Juan Carlos, Torres Martin, Maria Carmen, Campos, Jose, Gomez Puerta, Jose A, Yardimci, Gozd Kubra, Akar, Servet, Icacan, Ozan Cemal, Çelik, Selda, Vasylets, Viktoriia, Yeoh, Su-Ann, Vandevelde, Claire, Dunt, Sasha, Leeder, Jane, Macphie, Elizabeth, Salerno, Rosaria, Graver, Christine, Williams, Katie, O'Reilly, Sheila, Devine, Kirsty, Tyler, Jennifer, Warner, Elizabeth, Pilcher, James, Patel, Samir, Nikiphorou, Elena, Chadwick, Laura, Jones, Caroline Mulvaney, Harrison, Beverley, Thornton, Lucy, O'Kane, Diana, Fusi, Lucia, Low, Audrey, Horton, Sarah, Jatwani, Shraddha, Baig, Sara, Bajwa, Hammad, Berglund, Vernon, Dahle, Angela, Dorman, Walter, Hargrove, Jody, Hilton, Maren, Lebedoff, Nicholas, Leonard, Susan, Morgan, Jennifer, Pfeifer, Emily, Skemp, Archibald, Wilson, Jeffrey, Wolff, Anne, Cepeda, Eduardo, D'Silva, Kristin, Hsu, Tiffany, Patel, Naomi, Sparks, Jeffrey, Todd, Derrick, Wallace, Zachary, Hare, Denise, Calabrese, Cassandra, Adams, Christopher, Khosroshahi, Arezou, Kilian, Adam, White, Douglas, Winter, Melanie, Fields, Theodore, Siegel, Caroline, Daver, Nicole, Harvey, Melissa, Kramer, Neil, Lamore, Concetta, Hogarty, Suneya, Yeter, Karen, Wise, Leanna, Siddique, Faizah, Ban, Byung, Tanner, Tamar, Ruderman, Eric, Davis, William, Quinet, Robert, Scopelitis, Evangeline, Toribio Toribio, Karen, Webb-Detiege, Tameka, Zakem, Jerald, Abbass, Khurram, Kepecs, Gilbert, Miranda, Lilliam, Guma, Michael, Haikal, Ammar, Mody, Sushama, Mueller, Daric, Jayatilleke, Arundathi, Zell, JoAnn, Bays, Alison, Dao, Kathryn, Fatemeh, Ezzati, Parks, Deborah, Karp, David, Quiceno, Guillermo, Sattui, Sebastian E, Putman, Michael S, Seet, Andrea M, Gianfrancesco, Milena A, Beins, Kaley, Hill, Catherine, Liew, David, Mackie, Sarah L, Mehta, Puja, Neill, Lorna, Gomez, Gimena, Salinas, Maria Isabel Haye, Mariz, Henrique Ataide, de Sousa Studart, Samia Araujo, Araujo, Nafice Costa, Knight, Ann, Rozza, Davide, Quartuccio, Luca, Samson, Maxime, Bally, Stéphane, Maria, Alexandre TJ, Chazerain, Pascal, Hasseli, Rebecca, Müller-Ladner, Ulf, Hoyer, Bimba F, Voll, Reinhard, Torres, Rita Pinheiro, Luis, Mariana, Ribeirio, Sandra Lucia Euzebio, Sparks, Jeffrey A, Hsu, Tiffany Y-T, D’Silva, Kristin M, Patel, Naomi J, Gilbert, Emily, Almada, Maria Valenzuela, Duarte-García, Alí, Jacobsohn, Lindsay, Izadi, Zara, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Sirotich, Emily, Hausmann, Jonathan S, Sufka, Paul, Bhana, Suleman, Liew, Jean W, Grainger, Rebecca, Machado, Pedro M, Wallace, Zachary S, Yazdany, Jinoos, and Robinson, Philip C

Published
2021
Full Text
View/download PDF

26. Incidence of Pneumocystis JiroveciPneumonia in Patients With ANCA‐AssociatedVasculitis Initiating Therapy With Rituximab or Cyclophosphamide

Author

Nettleton, Elizabeth, Sattui, Sebastian E., Wallace, Zachary, and Putman, Michael

Abstract

This manuscript assesses the incidence of Pneumocystis jirovecipneumonia (PJP) among patients receiving contemporary treatment regimens for antineutrophil cytoplasmic antibody–associated vasculitis (AAV) and adverse events associated with PJP prophylaxis. Incident users of rituximab or cyclophosphamide for AAV were identified in the TriNetX electronic health records database from 2011 to 2022. The incidence rates (IRs) of PJP in the first 6 months of induction therapy with rituximab and/or cyclophosphamide and during postinduction maintenance therapy with rituximab were calculated. Cox proportional hazard models were used to estimate hazard ratios (HRs) and confidence intervals (CIs) for the risk of adverse events commonly associated with PJP prophylaxis. We identified 1,461 AAV cases who received induction therapy with rituximab (69.7%), cyclophosphamide (18.9%), or both (11.4%). Prophylaxis prescribed within 30 days of induction included trimethoprim‐sulfamethoxazole (30.7%), atovaquone (5.4%), dapsone (3.8%), and pentamidine (0.8%). During induction therapy, 10 cases of PJP were identified (IR 15.0 cases per 1,000 patient‐years); no deaths occurred. In adjusted analyses, those who received prophylaxis had a higher risk of leukopenia (HR 3.1; 95% CI 1.1–8.6), rash (HR 1.9; 95% CI 1.0–3.6), and nephropathy (HR 2.6; 95% CI 1.3–5.1) than those who did not. During rituximab maintenance therapy (n = 709), five cases of PJP were identified (IR 2.1 cases per 1,000 person‐years), one of whom died during the hospitalization associated with a PJP diagnosis. Rates of PJP in patients with AAV were lower than previously observed, and few cases occurred during rituximab maintenance therapy. PJP prophylaxis was associated with adverse events.

Published
2024
Full Text
View/download PDF

28. Giant cell arteritis can occur in people of colour

Author

Gill, Tiara, primary, Putman, Michael, additional, Sattui, Sebastian E, additional, Hamdulay, Shahir, additional, Conway, Richard, additional, Liew, David F L, additional, Sharma, Aman, additional, Stone, John H, additional, Mackie, Sarah L, additional, and Mehta, Puja, additional

Published
2023
Full Text
View/download PDF

30. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica

Author

Dejaco, Christian, primary, Kerschbaumer, Andreas, additional, Aletaha, Daniel, additional, Bond, Milena, additional, Hysa, Elvis, additional, Camellino, Dario, additional, Ehlers, Lisa, additional, Abril, Andy, additional, Appenzeller, Simone, additional, Cid, Maria C, additional, Dasgupta, Bhaskar, additional, Duftner, Christina, additional, Grayson, Peter C, additional, Hellmich, Bernhard, additional, Hočevar, Alojzija, additional, Kermani, Tanaz A, additional, Matteson, Eric L, additional, Mollan, Susan P, additional, Neill, Lorna, additional, Ponte, Cristina, additional, Salvarani, Carlo, additional, Sattui, Sebastian Eduardo, additional, Schmidt, Wolfgang A, additional, Seo, Philip, additional, Smolen, Josef S, additional, Thiel, Jens, additional, Toro-Gutiérrez, Carlos Enrique, additional, Whitlock, Madeline, additional, and Buttgereit, Frank, additional

Published
2023
Full Text
View/download PDF

33. An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists.

Author

Donskov, Agnete Overgaard, Mackie, Sarah Louise, Hauge, Ellen Margrethe, Toro-Gutiérrez, Carlos Enrique, Hansen, Ib Tønder, Hemmig, Andrea Katharina, Maas, Aatke Van der, Gheita, Tamer, Nielsen, Berit Dalsgaard, Douglas, Karen M J, Conway, Richard, Rezus, Elena, Dasgupta, Bhaskar, Monti, Sara, Matteson, Eric L, Sattui, Sebastian E, Matza, Mark, Ocampo, Vanessa, Gromova, Margarita, and Grainger, Rebecca

Subjects
GIANT cell arteritis diagnosis, GLUCOCORTICOIDS, PREDNISOLONE, MANAGEMENT information systems, GIANT cell arteritis, DECISION support systems, RHEUMATOLOGISTS, SURVEYS, COMPARATIVE studies, MEDICAL protocols, POLYMYALGIA rheumatica, DESCRIPTIVE statistics, CLINICAL trial registries
Abstract

Objectives To explore current management practices for PMR by general practitioners (GPs) and rheumatologists including implications for clinical trial recruitment. Methods An English language questionnaire was constructed by a working group of rheumatologists and GPs from six countries. The questionnaire focused on: 1: Respondent characteristics; 2: Referral practices; 3: Treatment with glucocorticoids; 4: Diagnostics; 5: Comorbidities; and 6: Barriers to research. The questionnaire was distributed to rheumatologists and GPs worldwide via members of the International PMR/Giant Cell Arteritis Study Group. Results In total, 394 GPs and 937 rheumatologists responded to the survey. GPs referred a median of 25% of their suspected PMR patients for diagnosis and 50% of these were returned to their GP for management. In general, 39% of rheumatologists evaluated patients with suspected PMR >2 weeks after referral, and a median of 50% of patients had started prednisolone before rheumatologist evaluation. Direct comparison of initial treatment showed that the percentage prescribing >25 mg prednisolone daily for patients was 30% for GPs and 12% for rheumatologists. Diagnostic imaging was rarely used. More than half (56%) of rheumatologists experienced difficulties recruiting people with PMR to clinical trials. Conclusion This large international survey indicates that a large proportion of people with PMR are not referred for diagnosis, and that the proportion of treatment-naive patients declined with increasing time from referral to assessment. Strategies are needed to change referral and management of people with PMR, to improve clinical practice and facilitate recruitment to clinical trials. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Patient‐Reported Outcomes in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Are the Answers in Front of Our Noses?

Author

Sattui, Sebastian E. and Wallace, Zachary S.

Subjects
PATIENT portals, CHURG-Strauss syndrome, MICROSCOPIC polyangiitis, ANTINEUTROPHIL cytoplasmic antibodies, PATIENT satisfaction
Abstract

This article discusses the use of patient-reported outcomes (PROs) in the assessment and treatment of antineutrophil cytoplasmic antibody-associated vasculitis (AAV). PROs, such as the Short Form 36 and the SinoNasal Outcome Test (SNOT-22), are being used in clinical trials to evaluate the effectiveness of treatments for AAV. The article highlights the variability in the use of PROs and the lack of standardized measures in AAV. It also explores the potential of PROs to predict future disease activity and relapse. The findings suggest that routine assessment of PROs may provide valuable insights into disease activity and improve patient care. Further research is needed to validate these findings and explore the role of biomarkers in predicting relapse. The article also raises questions about the significance of the sinonasal tract in AAV and the potential role of the nasal microbiome in disease activity. Overall, the study emphasizes the importance of incorporating the patient perspective in understanding and managing AAV. [Extracted from the article]

Published
2024
Full Text
View/download PDF

40. Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status

Author

Maguire, Sinead, primary, Al-Emadi, Samar, additional, Alba, Paula, additional, Aguiar, Mathia Cecilia, additional, Al Lawati, Talal, additional, Alle, Gelsomina, additional, Bermas, Bonnie, additional, Bhana, Suleman, additional, Branimir, Anic, additional, Bulina, Inita, additional, Clowse, Megan, additional, Cogo, Karina, additional, Colunga, Iris, additional, Cook, Claire, additional, Cortez, Karen J, additional, Dao, Kathryn, additional, Gianfrancesco, Milena, additional, Gore-Massey, Monique, additional, Gossec, Laure, additional, Grainger, Rebecca, additional, Hausman, Jonathon, additional, Hsu, Tiffany Y T, additional, Hyrich, Kimme, additional, Isnardi, Carolina, additional, Kawano, Yumeko, additional, Kilding, Rachael, additional, Kusevich, Daria A, additional, Lawson-Tovey, Saskia, additional, Liew, Jean, additional, McCarthy, Eoghan, additional, Montgumery, Anna, additional, Moyano, Sebastian, additional, Nasir, Noreen, additional, Padjen, Ivan, additional, Papagoras, Charalampos, additional, Patel, Naomi J, additional, Pera, Mariana, additional, Pisoni, Cecilia, additional, Pons-Estel, Guillermo, additional, Quiambao, Antonio L, additional, Quintana, Rosana, additional, Ruderman, Eric, additional, Sattui, Sebastian, additional, Savio, Veronica, additional, Sciascia, Savino, additional, Sencarova, Marieta, additional, Morales, Rosa Serrano, additional, Siddique, Faizah, additional, Sirotich, Emily, additional, Sparks, Jeffrey, additional, Strangfeld, Anja, additional, Sufka, Paul, additional, Tanner, Helen, additional, Tissera, Yohana, additional, Wallace, Zachary, additional, Werner, Marina L, additional, Wise, Leanna, additional, Worthing, Angus B, additional, Zell, JoAnn, additional, Zepa, Julija, additional, Machado, Pedro M, additional, Yazdany, Jinoos, additional, Robinson, Philip, additional, and Conway, Richard, additional

Published
2022
Full Text
View/download PDF

41. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

Author

DiIorio, Michael, primary, Kennedy, Kevin, additional, Liew, Jean W, additional, Putman, Michael S, additional, Sirotich, Emily, additional, Sattui, Sebastian E, additional, Foster, Gary, additional, Harrison, Carly, additional, Larché, Maggie J, additional, Levine, Mitchell, additional, Moni, Tarin T, additional, Thabane, Lehana, additional, Bhana, Suleman, additional, Costello, Wendy, additional, Grainger, Rebecca, additional, Machado, Pedro M, additional, Robinson, Philip C, additional, Sufka, Paul, additional, Wallace, Zachary S, additional, Yazdany, Jinoos, additional, Gore-Massy, Monique, additional, Howard, Richard A, additional, Kodhek, More A, additional, Lalonde, Nadine, additional, Tomasella, Laura-Ann, additional, Wallace, John, additional, Akpabio, Akpabio, additional, Alpízar-Rodríguez, Deshiré, additional, Beesley, Richard P, additional, Berenbaum, Francis, additional, Bulina, Inita, additional, Chock, Eugenia Yupei, additional, Conway, Richard, additional, Duarte-García, Alí, additional, Duff, Eimear, additional, Gheita, Tamer A, additional, Graef, Elizabeth R, additional, Hsieh, Evelyn, additional, El Kibbi, Lina, additional, Liew, David FL, additional, Lo, Chieh, additional, Nudel, Michal, additional, Singh, Aman Dev, additional, Singh, Jasvinder A, additional, Singh, Namrata, additional, Ugarte-Gil, Manuel F, additional, Hausmann, Jonathan S, additional, Simard, Julia F, additional, and Sparks, Jeffrey A, additional

Published
2022
Full Text
View/download PDF

44. Rapid Adoption of Telemedicine in Rheumatology Care During the COVID-19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees.

Author

Yeoh, Su-Ann, Yeoh, Su-Ann, Young, Kristen, Putman, Michael, Sattui, Sebastian, Conway, Richard, Graef, Elizabeth, Kilian, Adam, Konig, Maximilian, Sparks, Jeffrey, Ugarte-Gil, Manuel, Upton, Laura, Berenbaum, Francis, Bhana, Suleman, Costello, Wendy, Hausmann, Jonathan, Machado, Pedro, Robinson, Philip, Sirotich, Emily, Sufka, Paul, Yazdany, Jinoos, Liew, Jean, Grainger, Rebecca, Wallace, Zachary, Jayatilleke, Arundathi, Global Rheumatology Alliance, Yeoh, Su-Ann, Yeoh, Su-Ann, Young, Kristen, Putman, Michael, Sattui, Sebastian, Conway, Richard, Graef, Elizabeth, Kilian, Adam, Konig, Maximilian, Sparks, Jeffrey, Ugarte-Gil, Manuel, Upton, Laura, Berenbaum, Francis, Bhana, Suleman, Costello, Wendy, Hausmann, Jonathan, Machado, Pedro, Robinson, Philip, Sirotich, Emily, Sufka, Paul, Yazdany, Jinoos, Liew, Jean, Grainger, Rebecca, Wallace, Zachary, Jayatilleke, Arundathi, and Global Rheumatology Alliance

Abstract

ObjectiveTo evaluate the impact of telemedicine use during the coronavirus disease 2019 (COVID-19) pandemic on rheumatology trainees.MethodsA voluntary, anonymous, web-based survey was administered in English, Spanish, or French from August 19 to October 5, 2020. Adult and pediatric rheumatology trainees were invited to participate via social media and email. Using multiple-choice questions and Likert scales, the survey assessed prior and current telemedicine use, impact on training, and supervision after COVID-19 prompted rapid telemedicine implementation.ResultsSurveys were received from 302 trainees from 33 countries, with 83% in adult rheumatology training programs. Reported telemedicine use increased from 13% before the pandemic to 82% during the pandemic. United States trainees predominantly used video visits, whereas outside the United States telemedicine was predominantly audio only. Most (65%) evaluated new patients using telemedicine. More respondents were comfortable using telemedicine for follow-up patients (69%) than for new patients (25%). Only 39% of respondents reported receiving telemedicine-focused training, including instruction on software, clinical skills, and billing, whereas more than half of United States trainees (59%) had training. Postconsultation verbal discussion was the most frequent form of supervision; 24% reported no supervision. Trainees found that telemedicine negatively impacted supervision (50%) and the quality of clinical teaching received (70%), with only 9% reporting a positive impact.ConclusionsDespite widespread uptake of telemedicine, a low proportion of trainees received telemedicine training, and many lacked comfort in evaluating patients, particularly new patients. Inadequate supervision and clinical teaching were areas of concern. If telemedicine remains in widespread use, ensuring appropriate trainee supervision and teaching should be prioritized.

Published
2022

47. Supporting International Medical Graduates in Rheumatology: A Call to Action.

Author

Fernandez‐Ruiz, Ruth, Duarte‐García, Alí, Rolle, Noelle A., Sattui, Sebastian E., Saygin, Didem, Dowell, Sharon, Alexander, Swetha A., Kumar, Bharat, Danila, Maria I., and Singh, Namrata

Subjects
FOREIGN physicians, DIVERSITY & inclusion policies, WORK environment, SOCIAL support, VOCATIONAL guidance, INDIVIDUAL development, HEALTH services accessibility, RHEUMATOLOGY, PROFESSIONAL employee training, EMIGRATION & immigration, RHEUMATOLOGISTS, MEDICAL practice, CITIZENSHIP
Abstract

The article focuses on international medical graduates who are individuals who obtained their medical degree outside of the U.S., Puerto Rico or Canada and comprise more than one-third of the rheumatology workforce and fellows-in-training in the U.S. Topics include examines IMGs continue to face relatively limited opportunities for career growth and support.

Published
2023
Full Text
View/download PDF

48. COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

Author

Putman, Michael, Kennedy, Kevin, Sirotich, Emily, Liew, Jean W, Sattui, Sebastian E, Moni, Tarin T, Akpabio, Akpabio A, Alpizar-Rodriguez, Deshire, Angevare, Saskya, Beesley, Richard P, Berenbaum, Francis, Bulina, Inita, Chock, Yu Pei Eugenia, Conway, Richard, Duarte-García, Ali, Singh, Aman Dev, Duff, Eimear, Durrant, Karen L, Gheita, Tamer A, Hill, Catherine L, Howard, Richard, Hoyer, Bimba F, Hsieh, Evelyn, el Kibbi, Lina, Kilian, Adam, Kim, Alfred H J, Liew, David F L, Lo, Chieh, Mateus, Elsa F, Miller, Bruce, Mingolla, Serena, Nudel, Michal, Singh, Jasvinder A, Singh, Namrata, Ugarte-Gil, Manuel F, Wallace, John, Young, Kristen J, Zamora-Tehozol, Erick Adrian, Bhana, Suleman, Costello, Wendy, Grainger, Rebecca, Machado, Pedro M, Robinson, Philip C, Sufka, Paul, Wallace, Zachary S, Yazdany, Jinoos, Harrison, Carly, Larché, Maggie J, Levine, Mitchell, Foster, Gary, Thabane, Lehana, Hausmann, Jonathan S, Sparks, Jeffrey A, and Simard, Julia F

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results